Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Diluted Average) (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $133.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 23.08% to $133.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $133.6 million, a 23.08% increase, with the full-year FY2024 number at $114.5 million, up 19.02% from a year prior.
  • Shares Outstanding (Diluted Average) was $133.6 million for Q3 2025 at Centessa Pharmaceuticals, roughly flat from $133.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $133.7 million in Q2 2025 to a low of $90.5 million in Q1 2022.
  • A 4-year average of $105.7 million and a median of $96.2 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 1.12% in 2023, then skyrocketed 33.18% in 2025.
  • Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $93.4 million in 2022, then grew by 2.97% to $96.2 million in 2023, then rose by 19.02% to $114.5 million in 2024, then grew by 16.73% to $133.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Shares Outstanding (Diluted Average) are $133.6 million (Q3 2025), $133.7 million (Q2 2025), and $133.0 million (Q1 2025).